

INDICATIVE MASTER LIST OF ELIGIBLE ITEMS, AND AGREED LIST OF ACCEPTABLE EXPENDITURE ITEMS ('POSITIVE LIST'), FOR ADB FINANCING UNDER THE RAPID RESPONSE COMPONENT

The eligible items agreed for financing will include:

- (i) Advance market commitments and/or payments or procurement costs for vaccines acquired through the COVID-19 Vaccines Global Access Facility (irrespective of whether Nepal eventually procures vaccines through the facility).
- (ii) Vaccines that meet any of the eligibility criteria outlined in the linked document: Eligibility Criteria for Use of Funds under the Rapid Response Component.¹
 - (a) Vaccines that meet at least one of the eligibility criteria and will be potentially financed by the Asian Development Bank such as, Pfizer / Moderna vaccine, Oxford/AstraZeneca vaccine manufactured by the Serum Institute of India or SK bioscience, Sinopharm vaccine manufactured by Beijing Institute of Biological Products, and Johnson & Johnson's Janssen vaccine manufactured by authorized manufacturers, Sinovac vaccine etc.
 - (b) Vaccines being explored for procurement which may also be financed by the Asian Development Bank if they meet one of the eligibility criteria are Covovax vaccine manufactured by the Serum Institute of India, Sputnik V vaccine manufactured by Gamaleya Research Institute of Epidemiology and Microbiology or by Dr. Reddy's Laboratories, COVAXIN vaccine manufactured by Bharat Biotech International Limited, and others.
- (iii) Advance payments for vaccines that meet one of the eligibility criteria, and that will be procured from vaccine manufacturers and distributors (see item [ii]).
- (iv) International logistics and related services required for the transportation of eligible vaccines to designated delivery points in Nepal.
- (v) Indirect management fees, with reasonable percentage normally below 10% of the loan amount managed, charged as required by the United Nations agencies' financial regulations or similar authoritative guidelines.

¹ Eligibility Criteria for Use of Funds Under the Rapid Response Component (accessible from the list of linked documents in Appendix 2 of the report and recommendation of the President).